Search
Close this search box.
Search

Oncology

Invitae Multi-Cancer Panel

Hereditary Cancer Panel

The Invitae Multi-Cancer Panel is a genetic test that analyzes genes associated with hereditary predisposition to cancer development in organs such as the breast, ovary, prostate, intestine, skin, among others.

The analysis of genes offered in the panel helps confirm a clinical diagnosis of cancer predisposition, predict prognosis and disease progression, facilitate early diagnosis, and inform family planning.

Overview

The Invitae Multi-Cancer Panel analyzes specific genes to help determine your risk of developing cancer.

Pathogenic genetic variants significantly increase your likelihood of developing cancer.

Lifetime breast cancer risk¹

Colorectal cancer risk²

Lifetime colorectal cancer risk¹

Hover over the bars to see the values* (in %)

*Approximate values

1. NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic v1 .2023

2. NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High Risk Assessment: Colorectal v2.2023

5-10%

Between 5% and 10% of all cancers can be attributed to hereditary genetic variants or changes in a specific gene.¹ Cancer can run in families when individuals carry these variants. If you are concerned about cancer patterns in your family, genetic testing can provide more information about cancer risk.

 

Garber J. E., Offit K. Hereditary Cancer

Predisposition Syndromes.J. Clin. Oncol.
2005;23:276-292. doi:
10.1200/JCO.2005.10.042

69%

69% of patients at risk for Lynch syndrome were never advised to undergo genetic testing.

 

Knowledge and update of genetic counseling and counseling and colonoscopic screening amoung individuals at increased risk for Lynch syndrome and their endoscopists from the Family health promotion Project.
2016 Feb;111(2):285-93.

When Should You Consider This Test?

Consider this test in the following cases:

Personal history of cancer at a young age
Personal or family history of ovarian cancer, male breast cancer, or pancreatic cancer
Multiple cancers on the same side of the family
Ashkenazi Jewish ancestry
Concern about personal or family cancer history

Genes Analyzed

The panel includes:

70

Genes

AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CHEK2, CTNNA1, DICER1, EGFR, EPCAM, FH, FLCN, GREM1, HOXB13, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PDGFRA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL

Methodology

The methodology used for this test is as follows:

Sample:

Blood
Saliva
Extracted DNA

PREPARATION:

Blood: No fasting required.

Saliva: Fasting from liquids and food for 1 hour.

Extracted DNA: Consult.

TURNAROUND TIME:

Up to 21 calendar days

REQUIRED DOCUMENTS:

Medical request.

Type Description
Technique NGS + CNVs
Depth >100x
Coverage >99% of target regions
VuS Resolution Sanger, MLPA

Como solicitar o teste?

Contact Our Customer Services
Exatus Gene will send a collection kit and provide instructions for sample collection
We will retrieve the collected sample and send it to the laboratory for analysis
The report will be made available through the SysGene Portal and sent to your email